Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I added at the discounted price.
If the sp dips lower I’ll keep adding.
Go big or go home!
The volume being over 2M shares today makes me wonder if short covering at reduced prices is going on since we are close to UK approval related news.
Could also be other bargain hunters acting on the cheap shares.
Best wishes and prayers for a full and speedy recovery and thank you for clearly expressing why treatments like DCVax are so important for patients !
I guess your approach to the trial is similar to your approach to the negative narrative on nwbo and dcvax, which seems to be patients be damned if it means making some coin, imho.
You’d have trial patients continue with only SOC with no hope rather than how the trial, AT THE FDAs insistence required the crossover to DCVax?
I guess the fda has more compassion.
I believe your assertion is wrong and I will explain why.
The MHRA already approved the PIP, which is based on the very same trial design!
If the MHRA had any agita with the phase 3 trial they would not have approved the PIP.
Nice try to FUD but no cigar this time.
Yea baby!
Meeting held between NICE and nwbo early February to discuss next steps!
Step by step, inch by inch, forward progress!
It’s the running game now, picking up the yards, no Hail Mary passes required or desired!
The joint is jumping!
Exciting happenings such as the UK mhra and NiCE statuses, support for DCVax L by organizations, and Financial Times article on nwbo spoofing suit that FT’s huge following has read!
Spidey senses in overdrive!!!
Thanks for the due diligence and oddly enough it was in legalese that even I could understand
Yes very important point!
Imo and educated guessing, the spoofing would be integral to the HFT as a means to achieve the intended price trajectories, along with short sales and who knows what other tools of the trade.
No way they want to go through discovery because that’ll open Pandora’s box!
They would want to settle and take their chances with any others.
Besides, the real flood of cases will happen if they go through discovery and lose the case and pay substantial damages.
That would clear the path for any other companies that may have been harmed the same way!
Remember, they pay “relatively” small (tor them) fines all the time as part of doing business.
The spidey senses were right and they are still tingling stronger!
FT.com spoofing case article, brain organization support for fda approval of dcvaxL, news coverage starting,….FUDsters out in full court press trying to flood the boards with rehashed bs
NICE news
MHRA approval
Word is getting out and will build!
The snow ball has just begun to roll and grow imo.
The fly in the ointment is that the whole immuno response basis is that you want the patient’s own immune system to attack the patient’s own tumor, hence using the patient’s own tumor lysate, in order to attack all the targets of the patient’s tumor.
I mean there might be value if for some reason you can’t get the patient’s tumor, if using another person’s GBM tumor but as heterogenous and full of variants even GBM tumors are from the same patient taken at the same time from different points in the tumor, intuitively I would think the vaccine induced immune response would miss antigens and thus might not eradicate the tumor.
I don’t know if this cross patients scenario has ever been tried anywhere, and I assume better options would be applied if possible, but one day it might be tried if no better options are available.
I don’t know if exposing your own dendritic cells to a foreign tumor lysate would work at all unless there would be substantial overlap in the composition, but would the difference in dna factor in and preclude recognizing the tumor that exists in the patient being treated?
Way over my head!
The FUDsters could take a cue from another Dirty Dancing line:
When I’m wrong, I say I’m wrong!
I’m jumping in without knowing the context, however it might be useful to some ihub nwbo board readers to know that Fidelity has a retirement planning tool that runs Monte Carlo simulation analyses where you can look at the plan “results” for different market return scenarios.
For example, well below average market returns, below average, average, and above average.
I use the tool for another view of whether I’m likely to be ok through retirement (end of plan is the assumed age of passing of the plan participants, allowing independent ages reach spouse) and you enter your various assets and monthly/annual core and non core expenses, and any social security and pensions.
You can update your plan and rerun it anytime and you can save the plan output reports that show year by year the components of your income and projected expenses.
I guess this was a whole lot of answer for no question
Our future’s so bright
We got to wear shades!!!
Any day now will bring the start of a wave of good news and developments for DCVax and nwbo.
I can feel it, my spidey senses are tingling.
And it’s a good tingling!
I still think approval will come after the CHM meeting around the ides of March.
I come to praise nwbo, not to bury it
Et tu Brute
You FUDsters take note.
Should anyone, especially a young child who should have a lifetime to live and learn so much, have to wait longer or tragically miss out on the chance and hope to live a long time?
Please see the light and be constructive in your humanity! It’s not too late to be a better person.
Artificially controlled price for now, but the day is coming!
She should still be in place when the DCVax MAA is approved!
Hopefully with months to spare.
All in due time, like shortly after UK approval.
That only goes to show the importance and what a large net’s worth
Anyone catch Dr Ashkan today?
I guess you missed the mhra acknowledgment that they have the DCVax L MAA months after submission so that confirms it’s in process.
The “missing PR” is a figment of someone’s imagination or a false representation.
Good night to all and GLTA NWBO longs
You can say what you want but I don’t agree and the objective facts are there for due diligence and regardless of any arguments we are now confirmed in mhra and waiting on approval decision.
I’m not interested in debating FUD in my not so spare time.
Let’s agree to greatly disagree
The rigging of the trading appears to allow precise clamping of the sp, and also moving it up and down according to what appears to be programmable values.
And that’s without the extraordinary attack of May 10th 2022 which I believe is highlighted in the legal case.
When “it” happens we all will remember “wheezy, it’s the big one” but for opposite reasons
They didn’t gang up on those companies because they didn’t for whatever reasons.
Everyone has to limit their activities.
I can probably do research and come up with some guesses like easier target due to financial and trading exchange etc
But no point wasting my time.
I believe the share price is artificial and firmly manipulated.
I also believe this grip on share price will be broken and this year.
Reminds me of a childhood television show, Sonny Fox was the host (really dating myself) and I think their theme song was “put on a happy face” which means to focus on the positives and good attitude because the gray skies are gonna clear up and there’ll be sunshine all over the place!!!
It’s happening and the FUDsters know it but have to keep pushing negativity and false narratives.
It probably takes away some of their financial incentive assuming compensation based partially on numbers of responses.
Not only that LP should have a good sense of value.
Look at what BP paid for KITE and others like Bluebird, weren’t they bought out in e$15-$30 Billion range years before any approvals and I’m not sure they received approvals still, and that efficacious outcomes have been demonstrated yet?
DCVax/nwbo is ahead on all those factors, yes?
Your assessment is very plausible.
Personally I have not sold a share however I do have pressures that might have me sell 5% at about $5 per share or maybe hold and sell 10%-20% at $10.
I do believe the potential is much higher and plan to hold most shares.
Yes I agree 100%.
And they would love for nwbo to get their hands slapped or worse by the regulators, like they tried to setup a number of years ago when they fomented the premature “hyping” accusations and trying to drag the fda into it.
Perhaps not to appear to be marketing or hyping before regulators approve.
Toucan is not Aracaris, never was.
Aracaris is a new entity that I assume LP named, given the tie in to the toucan bird species, hence my assumption about the name, not in any way a business relationship.
As far as I know, Toucan the LLP was LP’s investment partnership entity for the purpose of LP and her partners to fund investments.
I have not studied the details and vagaries of Toucan (and I think there have been a Toucan 1, 2, etc.) but I think I remember something about LP dissolving Toucan, but that’s why I said “think” because I’m not sure and I don’t write down all the due diligence over the years.
Does that clear things up?
Btw, nwbo UK is part of nwbo.
Yes that’s what I said, that Aracaris is part of nwbo.
No, that’s not what I said.
I used to have positions in BMY, Pfizer, and other pharmaceuticals but only remain in Lilly, Abbvie, and Merck, with nwbo position being larger than the others combined.
If Lilly keeps flying, the relatively small number of shares might temporarily eclipse the current suppressed value of my position in nwbo.
In general the market seems to like Merck and its oncology assets and potential to grow their oncology related business.
The question remains whether Merck or the other BPs would fully nurture DCVax asap or throttle DCVax to optimize important existing products, unless they can benefit optimally (from the BP’s perspective) by combinations until and if DCVax’s market becomes bigger than lets say a keytruda.
I think we should trust LP to navigate these waters since chances are she’s the smartest person in most of the rooms she’s in, imho.
In support of your view, LP and LG are “mature” enough to know a transition to sustainable management should occur.
They can stay involved and very influential if (especially LP) desired, however the day to day work of management is going to mushroom with indications, trials, regulatory changes, etc.
Nwbo has to transition to a structure appropriate to the mushrooming needs of the business imho.